Result of AGM

RNS Number : 3820N
Diaceutics PLC
19 May 2020
 

 

19 May 2020

Diaceutics PLC

("Diaceutics" or the "Company")

 

Results of Annual General Meeting

 

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that all resolutions proposed at its Annual General Meeting held earlier today, were duly passed. 

 

Details of the proxy votes received on each resolution by Diaceutics' Registrar are set out below:

Resolution

For &
Discretionary

Against

Withheld

Total votes cast



Number of votes

%

Number of votes

%

Number of votes


1

Ordinary resolution to receive and consider the 2019 Financial Statements

50,023,247

100.00%

0

0.00%

0

50,023,247

2

Ordinary resolution to re-elect Julie Goonewardene as a director

49,984,878

99.92%

38,369

0.08%

0

50,023,247

3

Ordinary resolution to re-elect Charles Hindson as a director

49,969,009

100.00%

0

0.00%

54,238

49,969,009

4

Ordinary resolution to re-elect Mike Wort as a director

49,969,009

100.00%

0

0.00%

54,238

49,969,009

5

Ordinary resolution to re-elect Peter Keeling as a director

50,023,247

100.00%

0

0.00%

0

50,023,247

6

Ordinary resolution to re-elect Ryan Keeling as a director

49,984,878

99.92%

38,369

0.08%

0

50,023,247

7

Ordinary resolution to re-elect Philip White as a director

50,023,247

100.00%

0

0.00%

0

50,023,247

8

Ordinary resolution to re-appoint PricewaterhouseCoopers LLP as auditors

49,984,878

100.00%

0

0.00%

38,369

49,984,878

9

Ordinary resolution to authorise the directors to determine the remuneration of the auditors

50,007,378

100.00%

0

0.00%

15,869

50,007,378

10

Ordinary resolution to authorise the directors to allot shares

49,984,878

99.92%

38,369

0.08%

0

50,023,247

11

Special resolution to authorise the directors to disapply pre-emption rights

49,983,480

99.92%

39,767

0.08%

0

50,023,247

12

Special resolution to authorise the directors to purchase own shares

47,744,794

99.92%

39,453

0.08%

2,239,000

47,784,247

 

 

 

Enquiries

 

Diaceutics PLC 

 

Stuart Hunt, Head of Investor Relations 

Tel: +44 (0)7815 778 536 

 

 

Cenkos Securities PLC (Nomad & Broker)

Tel: +44(0)20 7397 8900

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Walbrook PR 

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy 

Tel: +44 (0)7876 741 001 

Paul McManus 

Tel: +44 (0)7980 541 893 

 

 

 

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGZZGMKFLNGGZM

Companies

Diaceutics (DXRX)
UK 100